Paclitaxel

Microtubule inhibitor

MECHANISM OF ACTION

Interferes with G2 mitotic phase

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

extra-renal; neutropenia, neuroapthy, alopecia, hypersensitivity

CARDIOVASCULAR ADVERSE EFFECTS

CHF in 5-15% at conventional doses -PMID: 29070990-- myocardial ischemia PMID: 36457122

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

eGFR < 60 ml/min , no adjustment is needed

NOTES/COMMENTS

PHARMACOKINETICS

Molecular Weight

853

Volume of Distribution

Plasma Protein Binding

89-98%

Metabolism

Bioavailability

Half-life elimination

13-20 hours

Time to peak

Excretion

Mostly via feces; Urine (14%)

Dialyzable?

Non dialyzable

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH